Ameritas Investment Partners Inc. Raises Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Ameritas Investment Partners Inc. grew its holdings in Illumina, Inc. (NASDAQ:ILMN) by 216.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 42,366 shares of the life sciences company’s stock after acquiring an additional 28,957 shares during the period. Ameritas Investment Partners Inc.’s holdings in Illumina were worth $4,422,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in ILMN. Thrivent Financial for Lutherans lifted its holdings in Illumina by 97.1% in the 2nd quarter. Thrivent Financial for Lutherans now owns 60,298 shares of the life sciences company’s stock worth $6,294,000 after purchasing an additional 29,709 shares in the last quarter. Sei Investments Co. grew its position in shares of Illumina by 37.3% during the second quarter. Sei Investments Co. now owns 97,681 shares of the life sciences company’s stock valued at $10,196,000 after purchasing an additional 26,538 shares in the last quarter. Pacer Advisors Inc. increased its holdings in shares of Illumina by 71.9% in the second quarter. Pacer Advisors Inc. now owns 31,762 shares of the life sciences company’s stock worth $3,315,000 after purchasing an additional 13,290 shares during the last quarter. Canada Pension Plan Investment Board lifted its position in shares of Illumina by 69.6% in the second quarter. Canada Pension Plan Investment Board now owns 473,750 shares of the life sciences company’s stock worth $49,450,000 after buying an additional 194,399 shares in the last quarter. Finally, Intech Investment Management LLC bought a new position in Illumina during the second quarter valued at approximately $313,000. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 2.4 %

Shares of NASDAQ:ILMN opened at $131.20 on Friday. The company has a market capitalization of $20.90 billion, a PE ratio of -16.10 and a beta of 1.15. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. Illumina, Inc. has a 12-month low of $89.00 and a 12-month high of $148.19. The business’s fifty day simple moving average is $125.25 and its 200-day simple moving average is $120.67.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.12 by $0.24. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same period in the prior year, the firm posted $0.32 earnings per share. The company’s quarterly revenue was down 5.4% on a year-over-year basis. As a group, equities research analysts predict that Illumina, Inc. will post 3.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on ILMN. Robert W. Baird upped their price objective on Illumina from $119.00 to $124.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Evercore ISI decreased their target price on shares of Illumina from $195.00 to $175.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 11th. UBS Group raised their price target on Illumina from $131.00 to $133.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Citigroup lifted their target price on Illumina from $140.00 to $155.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Finally, JPMorgan Chase & Co. cut their price target on shares of Illumina from $130.00 to $125.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Illumina currently has a consensus rating of “Moderate Buy” and an average price target of $151.05.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.